A study found that treating patients with rivaroxaban for 45 days after hospital discharge reducedthe rate of nonfatal blood clots, but had no effect on fatal blood clots.
A massive retrospective study compared several non-vitamin K antagonist oral anticoagulants (NOACs) to warfarin.
The September Small Doses brings you the latest news that affects pharmacists.
Stalled competition hurts consumers and may keep prices higher.
The EpiPen shortage is putting lives at risk and creating a back-up at some pharmacies. But solutions are on the horizon.
Apixaban (Eliquis) had the lowest overall risks out of direct oral anticoagulants (DOACs) versus warfarin (Coumadin) in a large study.
Using oral anticoagulants and nonsteroidal anti-inflammatory drugs (NSAIDs) together increases the risk for major bleeding and stroke in patients with atrial fibrillation (AF), according to a new analysis.
Small Doses is back, bringing you the pharmacy news you need in a way that works for you.
The drug is the first approved under the agency's new, quicker generic approval designation.
A Kentucky pharmacy owner was recently accused of making custom pain pills for pill mills.